AVECTAS Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 40

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $9.7M

  • Investors
  • 4

AVECTAS General Information

Description

Developer of cell engineering platform intended to enable the ex-vivo manufacture of gene-modified cell therapy products. The company's technology permeabilizes the target cell membrane and allows efficient transfer of cargo into cells whilst retaining very high levels of cell viability and functionality, enabling drug developers to develop potent engineered cell therapies at therapeutic volumes with minimal cell disruption.

Contact Information

Website
www.avectas.com
Formerly Known As
Profector Life Sciences
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Corporate Office
  • 3rd Floor Eolas Building, MaynoothWorks
  • Kildare, Maynooth University
  • Maynooth
  • Ireland

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AVECTAS Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 01-Apr-2022 $9.7M 000.00 000.00 Completed Generating Revenue
8. Later Stage VC (Series C) 16-Apr-2020 000.00 000.00 000.00 Completed Generating Revenue
7. Later Stage VC 09-Apr-2019 00.00 000.00 000.00 Completed Generating Revenue
6. Later Stage VC 27-Apr-2018 00.000 000.00 000.00 Completed Generating Revenue
5. Grant 01-Feb-2018 00.000 000.00 Completed Generating Revenue
4. Later Stage VC 21-Apr-2017 00.000 000.00 000.00 Completed Generating Revenue
3. Corporate 05-Jan-2015 0000 000.00 Completed Generating Revenue
2. Early Stage VC 14-Nov-2014 $2.37M $2.7M 00.000 Completed Startup
1. Early Stage VC 09-Oct-2013 $473K $338K 00.000 Completed Startup
To view AVECTAS’s complete valuation and funding history, request access »

AVECTAS Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 00,000,000 00.000000 00.0 00.0 00 00.0 00.000
Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Ordinary 000,000 00.000000 00.0 00.0 00 00.0 0.000
Ordinary 000,000 00.000000 00.0 00.0 00 00.0 0.000
Ordinary 00,000 00.000000 00.00 00.00 00 00.00 0.000
Ordinary 197,800 $0.001100 $1.28 $1.28 1x $1.28 1.09%
Ordinary 105,000 $0.001100 $1.56 $1.56 1x $1.56 0.58%
To view AVECTAS’s complete cap table history, request access »

AVECTAS Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of cell engineering platform intended to enable the ex-vivo manufacture of gene-modified cell therapy products
Drug Delivery
Maynooth, Ireland
40 As of 2024
000.00
000.00 0000-00-00
0000000000 0 000.00

000000

s nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
0000000000000
Roslin, United Kingdom
0 As of 0000
00.000
000000 0

00000

lit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidat
0000 000000000
Pittsburgh, PA
0 As of 0000
00.000
0000000000 0 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AVECTAS Competitors (6)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ProFactor Pharma Venture Capital-Backed Roslin, United Kingdom 0 00.000 000000 0
Sharp Therapeutics Venture Capital-Backed Pittsburgh, PA 0 00.000 0000000000 0 00.000
Synthego Venture Capital-Backed Redwood City, CA 000 00000 00000000000 00000
Voyager Therapeutics Corporation Cambridge, MA 000 00000 00000000 00000
Applied StemCell Private Equity-Backed Milpitas, CA 00 000.00 000000000000 000.00
To view AVECTAS’s complete competitors history, request access »

AVECTAS Patents

AVECTAS Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3225582-A1 Spray nozzle Pending 24-Jun-2021 000000000
AU-2022299660-A1 Spray nozzle Pending 24-Jun-2021 000000000
EP-4359041-A1 Spray nozzle Pending 24-Jun-2021 000000000
CA-3206787-A1 Delivery platform Pending 01-Feb-2021 000000000
AU-2022213019-A1 Delivery platform Pending 01-Feb-2021 C12M33/04
To view AVECTAS’s complete patent history, request access »

AVECTAS Executive Team (8)

Name Title Board Seat Contact Info
Michael Maguire Ph.D Co-Founder, Chief Executive Officer & Board Member
Justin McCue Ph.D Chief Technology Officer
Eoin Heffernan Director of Finance & Strategic Operations
Mary Martin Ph.D Executive Chairman & Board Member
Ann Brady Ph.D Chief Business Officer & Board Member
You’re viewing 5 of 8 executive team members. Get the full list »

AVECTAS Board Members (7)

Name Representing Role Since
Ann Brady Ph.D Self Chief Business Officer & Board Member 000 0000
Barry Leonard Self Board Member 000 0000
Barry Wohl Self Board Member 000 0000
Eunan Maguire Adapt Pharma Board Member 000 0000
Mary Martin Ph.D AVECTAS Executive Chairman & Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

AVECTAS Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AVECTAS Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Seamus Mulligan Angel (individual) Minority 000 0000 000000 0
Horizon 2020 SME Instrument Government 000 0000 000000 0
Adapt Pharma Corporation Minority 000 0000 000000 0
David Brabazon Angel (individual) Minority 000 0000 000000 0
To view AVECTAS’s complete investors history, request access »

AVECTAS FAQs

  • When was AVECTAS founded?

    AVECTAS was founded in 2011.

  • Who is the founder of AVECTAS?

    Michael Maguire Ph.D and Shirley O'Dea Ph.D are the founders of AVECTAS.

  • Who is the CEO of AVECTAS?

    Michael Maguire Ph.D is the CEO of AVECTAS.

  • Where is AVECTAS headquartered?

    AVECTAS is headquartered in Maynooth, Ireland.

  • What is the size of AVECTAS?

    AVECTAS has 40 total employees.

  • What industry is AVECTAS in?

    AVECTAS’s primary industry is Drug Delivery.

  • Is AVECTAS a private or public company?

    AVECTAS is a Private company.

  • What is the current valuation of AVECTAS?

    The current valuation of AVECTAS is 000.00.

  • What is AVECTAS’s current revenue?

    The current revenue for AVECTAS is 00000.

  • How much funding has AVECTAS raised over time?

    AVECTAS has raised $61.2M.

  • Who are AVECTAS’s investors?

    Seamus Mulligan, Horizon 2020 SME Instrument, Adapt Pharma, and David Brabazon have invested in AVECTAS.

  • Who are AVECTAS’s competitors?

    ProFactor Pharma, Sharp Therapeutics, Synthego, Voyager Therapeutics, and Applied StemCell are some of the 6 competitors of AVECTAS.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »